Dr Reddys Laboratories: The Winning Streak Continues (RDY)
Dr Reddys Laboratories (NYSE:RDY) traded at a new 52-week high today of $39.32. So far today approximately 54,000 shares have been exchanged, as compared to an average 30-day volume of 244,000 shares.
Dr Reddys Laboratories (NYSE:RDY) is currently priced 1.6% above its average consensus analyst price target of $38.50. The stock should discover initial support at its 50-day moving average (MA) of $37.42 and subsequent support at its 200-day MA of $34.63.
Dr. Reddy's Laboratories Limited provides a complete range of pharmaceutical services. The Company manufactures bulk drugs and formulations including verapamil and cephalexin. The Company also manufactures and exports molecules such as norfloxacin, ciprofloxacin, and varieties of semi-synthetic penicillin. The Company markets its products in India and around the world.
Over the past year, Dr Reddys Laboratories has traded in a range of $28.72 to $39.32 and is now at $39.11, 36% above that low. The 200-day and 50-day moving averages have moved 0.36% higher and 0.28% higher over the past week, respectively.
SmarTrend is tracking the current trend status for Dr Reddys Laboratories and will alert subscribers who have RDY in their portfolio or watchlist when shares have changed trend direction.
Keywords: 52 week high/lows dr reddys laboratories